Skip to main content
# Table 1 Characteristics of included randomized trials of acupuncture for ulcerative colitis

Study ID | Year | Gender male/female | Sample size | Age (mean or range, yrs) | Course of disease (mean or range) | Course of treatment, days | Intervention vs. Control | Outcomes | Acupuncture intervention details | Control measures | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

Acupuncture point [25] | Acupuncture on one or both sides of the body | Duration of each treatment | Frequency | With or without conventional medicine | ||||||||||

RenY2014 | 2014 |
I:10/14 C:12/12 |
I:24 C:24 |
I:46.25 ± 15.11 C:50.2 ± 14.19 |
I:5.08 ± 2.1 years C:4.83 ± 1.74 years | 46 | Acupuncture + mesalazine vs. mesalazine | Clinical effect, activity index for UC, TCM syndrome score, colonoscopy curative effect, mucosal pathology, adverse effects | BL23, BL20, BL25, BL21, SP4, ST25, ST36, KI3, CV12, CV4 | both sides | 30 min | 1 time/day | Y | mesalazine: 1 time/day, 1.0 g/time |

JiaJN2015 | 2015 |
I:16/16 C:18/14 |
I:32 C:32 |
I:28–60 C:24–57 |
I:1–8 years C:1–7 years | 60 | Acupuncture + mesalazine vs. mesalazine | Clinical effect, T Cell subsets | CV3, CV4, CV6, ST25, SP15, BL25, ST36, ST37, SP6, LR3 | NR | 30 min | 1 time/day | Y | mesalazine: 4 times/day, 1.0 g/time |

YangSQ2012 | 2012 |
I:14/16 C:15/15 |
I:30 C:30 |
I:24–49 C:25–53 |
I:0.5–5 years C:0.7–6 years | 28 | Acupuncture + mesalazine vs. mesalazine | Clinical effect, clinical symptom score, colonoscopy curative effect, self-rating depression scale, adverse effects | Selected the frontal area as the therapeutic area by seven - area division of the head acupoints | NR | 6 h | NR | Y | mesalazine: 4 times/day, 1.0 g/time |

XueLZ2018 | 2018 |
I:25/22 C:24/23 |
I:47 C:47 |
I:28–75(40.3 ± 13.9) C:29–74(40.1 ± 12.8) | I:NRC:NR | 14 | Acupuncture vs. metronidazole + sulfasalazine | Clinical effect, adverse effects | CV4, CV6, GV1, BL25, ST25, SP6, ST36 | NR | 20 min | 1 time/day | N | metronidazole: 3 times/day, 0.2 g/time; sulfasalazine: 3 times/day,0.2 g/time |

LiuXH2013 | 2013 |
I:29/33 C:30/32 |
I:62 C:62 |
I:23–76(50.67 ± 6.82) C:24–74(51.14 ± 5.46) |
I:9–19(13.63 ± 5.16) months C:9–20(14.10 ± 5.22) months | – | Acupuncture vs. metronidazole + sulfasalazine | Clinical effect, adverse effects | CV4, CV6, ST25, BL25, GV1, ST36, SP6 | NR | 10 -30 min | 2 times/day | N | metronidazole: 3 times/day, 2-3 g/time; sulfasalazine: 3 times/day, The starting dose is 2–3 g/day, which can be increased to 4–6 g/day according to the patient’s condition. After the patient’s condition is stable, the dosage can be reduced to 1.5 to 2 g/day |

LiCH2017 | 2017 |
I:25/25 C:26/24 |
I:50 C:50 |
I:27–75(45.5 ± 4.5) C:27–76(46.8 ± 4.2) |
I:9–18(13 ± 1.5) months C:10–18(12 ± 1.8) months | – | Acupuncture vs. metronidazole + sulfasalazine | Clinical effect, pathological change ratio | CV4, CV6, ST25, GV1, BL25, SP6, ST36 | NR | 10-30 min | 2 times/day | N | metronidazole: 3 times/day, 0.2 g/time; sulfasalazine: 3 times/day, 2.0 g/time |

ZhangZZ2018 | 2018 |
I:29/21 C:27/23 |
I:50 C:50 |
I:32–66(44.1 ± 3.2) C:31–65(43.6 ± 3.0) |
I:1–9(3.6 ± 1.5) months C:1–8(3.5 ± 1.7) months | 14 | Acupuncture vs. mesalazine | Clinical effect, IL-2 | ST25, ST36), GV1, SP6 | NR | 16-22 min | 1 time/day | N | mesalazine: 3 times/day, 1.0–2.0 g/time |

WangMC2017 | 2017 |
I:12/13 C:17/8 |
I:25 C:25 |
I:38–74(56.8 ± 2.4) C:36–69(52.5 ± 3.8) |
I:1 month-4 years C:1 month-3 years | 10 | Acupuncture vs. mesalazine | Clinical effect, adverse effects | ST25, SP6, GV1, ST36, BL18, BL20, BL23 | NR | 20 min | 1 time/day | N | mesalazine: 3 times/day, 2.0 g/time |

LuanBY2016 | 2016 |
I:13/12 C:14/11 |
I:25 C:25 |
I:26–42(34 ± 5.75) C:23–42(31.28 ± 6.13) |
I:NR C:NR | 56 | Acupuncture vs. mesalazine | Clinical effect, adverse effects | SP4, KI3, ST36, CV4, ST25, BL16, BL20, BL21, BL22, BL25, GV2, GV6 | NR | 30 min | 1 time/day | N | mesalazine: 4 times/day, 1.0 g/time |

ZhangHC2009 | 2009 |
I:23/17 C:25/15 |
I:40 C:40 |
I:20–65(42.64 ± 6.9) C:19–67(38.73 ± 7.5) |
I:2.2–7.9(3.9 ± 2.3) years C:2.2–7.4(4.1 ± 1.7) years | 28 | Acupuncture vs. sulfasalazine | Clinical effect, adverse effects | Gastric region was selected according to functional localization of cerebral cortex | NR | 5-10 min | 1 time/day | N | sulfasalazine: 3 times/day, 2.0 g/time |

YanZL2018 | 2018 |
I:25/20 C:23/22 |
I:50 C:50 |
I:25–78(42.6 ± 11.7) C:26–77(41.3 ± 12.5) |
I:NR C:NR | 14 | Acupuncture + metronidazole + sulfasalazine vs. metronidazole + sulfasalazine | Clinical effect | ST25, BL25, GV1, CV6, CV4, ST36, SP6 | NR | 20 min | 1 time/day | Y | metronidazole: 3 times/day,0.2 g/time; sulfasalazine: 3 times/day, 0.2 g/time |

ZhangCY2018 | 2018 |
I:30/20 C:26/24 |
I:50 C:50 |
I:34–70(46.5 ± 0.5) C:35–69(45.6 ± 0.01) |
I:9 days-2 years (1.2 ± 0.01) years C:10 days-3 years (2.1 ± 0.01) years | 30 | Acupuncture + metronidazole vs. metronidazole | Clinical effect, adverse effects | CV4, CV6, ST25, GV1, BL25, SP6, ST36 | NR | 10-30 min | 2 times/day | Y | metronidazole: 3 times/day,0.2 g/time |

PangHM2020 | 2020 |
I:16/14 C:19/11 |
I:30 C:30 |
I: 41.63 ± 12.86 C: 43.33 ± 15.51 |
I: 36.90 ± 20.94 months C: 38.03 ± 18.42 months | 30 | Acupuncture + mesalazine vs. mesalazine | Clinical effect, Baron score | BL31, BL32, BL33,BL34 | both sides | 30 min | 1time/2 days | Y | mesalazine: 4 times/day, 1.0 g/time |